Clinical trial tests injectable vs oral HIV medications
10 May 2019 | By European Pharmaceutical Review
A new clinical trial will determine if monthly injections of anti-viral drugs are more effective at suppressing the HIV virus than daily pills.
List view / Grid view
ViiV Healthcare
ViiV Healthcare submits regulatory applications for HIV two-drug regimen
6 June 2017 | By Niamh Marriott, Junior Editor
Regulatory submissions to the EMA and FDA for a single-tablet, two-drug regimen of dolutegravir & rilpivirine for the maintenance treatment of HIV...
ViiV Healthcare to evaluate injectable HIV treatment
23 November 2016 | By Niamh Louise Marriott, Digital Content Producer
The two studies, FLAIR and ATLAS, will examine the safety and efficacy of monthly dosing with the two-drug, injectable regimen in both treatment-naïve...
Global dual-drug trial aims to advance HIV treatment
16 August 2016 | By ViiV Healthcare
ViiV Healthcare is undertaking two identical studies as part of a global phase III programme comparing a two-drug regimen of dolutegravir plus lamivudine, with a three-drug regimen of dolutegravir (Tivicay), plus the fixed-dose tablet tenofovir/emtricitabine (Truvada), to support regulatory filings as a treatment for HIV, for adults who have had…
Triumeq demonstrates superior efficacy for treating women with HIV
19 July 2016 | By Victoria White, Digital Content Producer
Triumeq demonstrated superior efficacy compared with ATV/r plus TDF/FTC in 495 treatment-naïve women living with HIV...
From HIV to oncology: widening access through flexible IP
28 April 2016 | By Jon Pender, VP Government Affairs, GSK
Jon Pender, GSK, discusses how a flexible and thoughtful approach to IP can help get medicines to the poorest and hardest-to-reach patients around the world...
ViiV and Janssen progress two drug injectable HIV-1 treatment
8 January 2016 | By Victoria White
ViiV Healthcare has formalised its collaboration with Janssen for the Phase III investigation and commercialisation of the injectable formulations of cabotegravir and rilpivirine...
BMS divests its HIV R&D assets to ViiV Healthcare
18 December 2015 | By Victoria White
ViiV will pay to Bristol-Myers Squibb upfront payments totaling $350 million with potential development and regulatory milestone payments of up to $518 million for the clinical assets and up to $587 million for the discovery and preclinical programmes...
Results announced for two drug injectable regimen for HIV maintenance therapy
3 November 2015 | By Victoria White
Results from the study show that cabotegravir and rilpivirine were comparable in maintaining viral suppression rates to a three drug oral regimen...
Switching to once-daily Triumeq maintains HIV viral suppression
23 September 2015 | By Victoria White
A Phase IIIb/IV study demonstrated that viral suppression was non-inferior for patients switching to once-daily Triumeq from an antiretroviral therapy...
ViiV Healthcare and Desano manufacturing agreement will bring competitive supply of dolutegravir to China
3 July 2015 | By Victoria White
ViiV Healthcare and Desano Pharmaceuticals have announced a strategic manufacturing agreement to enable production of dolutegravir in China...
ViiV Healthcare announces new grants in support of ending mother to child transmission of HIV
27 November 2014 | By ViiV Healthcare
Landmark number of grants awarded for 2015 as the Positive Action for Children Fund hits 5 year milestone...
ViiV Healthcare receives EU marketing authorisation for Triumeq® (dolutegravir/abacavir/lamivudine), a new once-daily single-pill regimen for the treatment of HIV
5 September 2014 | By GlaxoSmithKline
ViiV Healthcare announced that the European Commission has granted marketing authorisation for Triumeq® (dolutegravir 50mg / abacavir 600mg / lamivudine 300mg) tablets...
ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection
26 August 2014 | By GlaxoSmithKline
ViiV Healthcare announced that the US Food and Drug Administration has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection...
ViiV Healthcare presents phase III data comparing once-daily maraviroc in combination with darunavir/ritonavir
22 July 2014 | By GlaxoSmithKline
...with emtricitabine/tenofovir plus darunavir/ritonavir in treatment-naïve adults with HIV-1.
Follow: